Magnus Ekström1,2,3, Fredrik Nilsson2, Amy A Abernethy4, David C Currow3. 1. 1 Division of Respiratory Medicine and Allergology, Department of Clinical Sciences, Lund University, Lund, Sweden. 2. 2 Department of Medicine, Blekinge Hospital, Karlskrona, Sweden. 3. 3 Discipline, Palliative, and Supportive Services, Flinders University, Adelaide, Australia; and. 4. 4 Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, North Carolina.
Abstract
RATIONALE: Patients with chronic obstructive pulmonary disease (COPD) commonly suffer from breathlessness, deconditioning, and reduced health-related quality of life (HRQL) despite best medical management. Opioids may relieve breathlessness at rest and on exertion in COPD. OBJECTIVES: We aimed to estimate the efficacy and safety of opioids on refractory breathlessness, exercise capacity, and HRQL in COPD. METHODS: This was a systematic review and metaanalysis using Cochrane methodology. We searched Cochrane Central Register of Controlled Trials, MEDLINE, and Embase up to 8 September, 2014 for randomized, double-blind, placebo-controlled trials of any opioid for breathlessness, exercise capacity, or HRQL that included at least one participant with COPD. Effects were analyzed as standardized mean differences (SMDs) with 95% confidence intervals (CIs) using random effect models. MEASUREMENTS AND MAIN RESULTS: A total of 16 studies (15 crossover trials and 1 parallel-group study, 271 participants, 95% with severe COPD) were included. There were no serious adverse effects. Breathlessness was reduced by opioids overall: SMD, -0.35 (95% CI, -0.53 to -0.17; I(2), 48.9%), by systemic opioids (eight studies, 118 participants): SMD, -0.34 (95% CI, -0.58 to -0.10; I(2), 0%), and less consistently by nebulized opioids (four studies, 82 participants): SMD, -0.39 (95% CI, -0.71 to -0.07; I(2), 78.9%). The quality of evidence was moderate for systemic opioids and low for nebulized opioids on breathlessness. Opioids did not affect exercise capacity (13 studies, 149 participants): SMD, 0.06 (95% CI, -0.15 to 0.28; I(2), 70.7%). HRQL could not be analyzed. Findings were robust in sensitivity analyses. Risk of study bias was low or unclear. CONCLUSIONS: Opioids improved breathlessness but not exercise capacity in severe COPD.
RATIONALE: Patients with chronic obstructive pulmonary disease (COPD) commonly suffer from breathlessness, deconditioning, and reduced health-related quality of life (HRQL) despite best medical management. Opioids may relieve breathlessness at rest and on exertion in COPD. OBJECTIVES: We aimed to estimate the efficacy and safety of opioids on refractory breathlessness, exercise capacity, and HRQL in COPD. METHODS: This was a systematic review and metaanalysis using Cochrane methodology. We searched Cochrane Central Register of Controlled Trials, MEDLINE, and Embase up to 8 September, 2014 for randomized, double-blind, placebo-controlled trials of any opioid for breathlessness, exercise capacity, or HRQL that included at least one participant with COPD. Effects were analyzed as standardized mean differences (SMDs) with 95% confidence intervals (CIs) using random effect models. MEASUREMENTS AND MAIN RESULTS: A total of 16 studies (15 crossover trials and 1 parallel-group study, 271 participants, 95% with severe COPD) were included. There were no serious adverse effects. Breathlessness was reduced by opioids overall: SMD, -0.35 (95% CI, -0.53 to -0.17; I(2), 48.9%), by systemic opioids (eight studies, 118 participants): SMD, -0.34 (95% CI, -0.58 to -0.10; I(2), 0%), and less consistently by nebulized opioids (four studies, 82 participants): SMD, -0.39 (95% CI, -0.71 to -0.07; I(2), 78.9%). The quality of evidence was moderate for systemic opioids and low for nebulized opioids on breathlessness. Opioids did not affect exercise capacity (13 studies, 149 participants): SMD, 0.06 (95% CI, -0.15 to 0.28; I(2), 70.7%). HRQL could not be analyzed. Findings were robust in sensitivity analyses. Risk of study bias was low or unclear. CONCLUSIONS: Opioids improved breathlessness but not exercise capacity in severe COPD.
Entities:
Keywords:
breathlessness; chronic obstructive pulmonary disease; exercise capacity; opioids; quality of life
Authors: Capucine Morélot-Panzini; Carl R O'Donnell; Robert W Lansing; Richard M Schwartzstein; Robert B Banzett Journal: Respir Physiol Neurobiol Date: 2017-10-12 Impact factor: 1.931
Authors: Cornelia A Verberkt; Marieke H J van den Beuken-van Everdingen; Jos M G A Schols; Niels Hameleers; Emiel F M Wouters; Daisy J A Janssen Journal: JAMA Intern Med Date: 2020-10-01 Impact factor: 21.873
Authors: Anand S Iyer; James Nicholas Dionne-Odom; Dina M Khateeb; Lanier O'Hare; Rodney O Tucker; Cynthia J Brown; Mark T Dransfield; Marie A Bakitas Journal: J Palliat Med Date: 2019-10-29 Impact factor: 2.947